Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KLA Corp. (KLAC) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

DENTSPLY SIRONA IncTrade

Price performance (Past 24H)

Key statistics

KLA Corp. vs DENTSPLY SIRONA Inc — how do they compare? KLA Corp. trades at $195.95 (market cap $256.72B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: KLA Corp. is far larger — about 148.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and DENTSPLY SIRONA Inc for 72 Days on average.

KLACXRAY
Market Cap
$256.72B$1.73B
Volume
9,970,7536,198,582
Sector
TechnologyHealth
52-Week High
$301.71$14.68
52-Week Low
$98.28$8.52
Typical Hold Time
60 Days72 Days
Enterprise Value
$257.97B$3.80B
Dividend Yield
0.47%5.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KLA Corp.

KLA Corporation (KLAC) trades at $195.57, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $193. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, revenue growth accelerating to $12.16B in 2025, and exceptional profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57B backlog and competitive positioning against AMAT and ASML.

KLA presents a compelling growth opportunity with analyst consensus price target of $223.88 (14.5% upside) and strong institutional support, though elevated valuation ratios (P/E 53.75, P/S 19.12) and semiconductor cycle sensitivity warrant caution. The stock's outlook remains positive driven by AI infrastructure spending and advanced packaging growth, with key risks including competition intensity and potential margin pressure from increased investments.

DENTSPLY SIRONA Inc

DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.

XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KLAC
95% Buy5% Sell
Avg holding period · 60 Days
XRAY

No sentiment data available yet.

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC →

About DENTSPLY SIRONA Inc

Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters

Read more on XRAY →